Jove
Visualize
Contact Us

Related Experiment Videos

[Therapeutic agents for hyperphosphatemia].

Satoshi Kurihara1

  • 1Division of Nephology, Kasukabe-Shuwa Hospital.

Clinical Calcium
|March 19, 2005
PubMed
Summary

Sevelamer hydrochloride is a novel phosphate binder for dialysis patients, effectively lowering phosphorus levels without aluminum or calcium. It also improves cardiovascular health by reducing calcification progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Viral Membrane-Targeting Amphipathic Helical Peptide Ligands for Colorimetric Sandwich Assays of Influenza A Virus Particles.

ACS sensors·2026
Same author

Regulation of myocardial contraction as revealed by intracellular Ca<sup>2+</sup> measurements using aequorin.

The journal of physiological sciences : JPS·2025
Same author

Correction: Regulation of myocardial contraction as revealed by intracellular Ca<sup>2+</sup> measurements using aequorin.

The journal of physiological sciences : JPS·2024
Same author

Regulation of myocardial contraction as revealed by intracellular Ca<sup>2+</sup> measurements using aequorin.

The journal of physiological sciences : JPS·2024
Same author

Prevalence of COVID-19 Mimics in the Emergency Department.

Internal medicine (Tokyo, Japan)·2021
Same author

Sequential semi-supervised segmentation for serial electron microscopy image with small number of labels.

Journal of neuroscience methods·2021
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Nephrology
  • Internal Medicine
  • Pharmacology

Context:

  • Hyperphosphatemia is a common complication in dialysis patients, leading to secondary hyperparathyroidism.
  • Traditional phosphate binders like aluminum hydroxide and calcium compounds have limitations, including side effects and hypercalcemia.
  • There is a clinical need for phosphate binders free of aluminum and calcium.

Purpose:

  • To introduce and evaluate sevelamer hydrochloride (SH) as a novel aluminum-free and calcium-free phosphate binder.
  • To assess the efficacy and safety of SH in managing hyperphosphatemia and its complications in hemodialysis patients.

Summary:

  • Sevelamer hydrochloride (SH) is a non-absorbed, aluminum-free, and calcium-free phosphate binder.
  • Short-term studies show SH is effective in reducing serum phosphorus levels, improving the calcium x phosphorus product, and positively impacting lipid metabolism.
  • A long-term study demonstrated that SH attenuates the progression of coronary and aortic calcification in hemodialysis patients.

Impact:

  • SH offers a safer alternative for managing hyperphosphatemia in dialysis patients, potentially reducing the risk of secondary hyperparathyroidism progression.
  • This agent may play a crucial role in mitigating cardiovascular events and mortality associated with chronic kidney disease.
  • The findings support the use of SH for long-term management of hyperphosphatemia and cardiovascular risk reduction in hemodialysis patients.

Related Experiment Videos